Kancera changes Certified Adviser to Redeye AB
2025-03-14
Kancera AB (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on April 1, 2025.
About Kancera AB (publ)
Kancera is developing a new class of anti-inflammatory drugs in the field of cardiovascular diseases. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company’s Certified Adviser.
For further information:
Visit Kancera’s website: www.kancera.com
or contact:
ir@kancera.com or phone: +46 (0)8-5012 60 80